Web Content Management
PRODUCTS
-
Delivering on the promise of cell and gene therapy
Germfree is a leader in creating mobile and modular facilities specifically for cell and gene therapy (CGT) manufacturing. As CGT sits at the crossroads of medical research and pharmaceutical development, it demands highly specialized cleanroom designs. These designs must focus on efficient workflows, strict separation procedures, and rigorous aseptic processing to ensure the best results. Despite the quick growth and logistical challenges in the CGT field, Germfree’s mobile solutions effectively tackle these issues. They enable distributed manufacturing, ease the collection of patient cells, and help make CGT treatments accessible globally.
-
Strategic product development and CMC regulatory planning start early on at the pre-IND stage and apply to the entire development lifecycle through to post-approval.
-
The Challenge: Building Scalable Viral Vector Programs
Cell and gene therapies offer unprecedented hope for previously untreatable diseases. At the heart of many of these advanced therapies, including both gene therapies and gene-modified cell therapies, are viral vectors, particularly Adeno-Associated Vectors (AAV) and Lentiviral Vectors (LVV), which serve as crucial gene-delivery vehicles.
-
Using Document Change Control Software in Regulated Environments
Change is important in any business, but it is especially critical in life science, manufacturing, and other regulated companies, which are required to "control" change as part of compliance. This is why many companies are turning to document change control software to help them address the complexity of change control.
In regulated environments, the term "document change control" may refer to the document management or document control process, or it may to refer to the change control process, which involves rigorous documentation. Either way, most companies need document change control software to manage these processes.
-
We want your product to move through the regulatory process, gaining approvals and ultimately helping patients. Using our industry leading knowledge and skills, we will meet you where you are – gaining approval: for the first in human trials, in development, at scientific advice, at the end of phase 2, or post approval. At every level, our scientific expertise and in-depth knowledge of therapeutic backgrounds have guided every client we have to a successful outcome.
WHITE PAPERS AND CASE STUDIES
-
MilliporeSigma's 97-Day Implementation Success Story
Read how MilliporeSigma transformed validation processes with a digital validation system to achieve compliance in just 97 days, as well as learn key takeaways from their swift transition.
-
Metastatic Breast Cancer Rates Show Disparities Between Black And White Patients
Given that age and screening have observable but not fully explicable effects on risk, a new analysis investigates the racial disparities in breast cancer outcomes.
-
How To Get Products To Patients Faster With A Connected QMS
BioBridge Global faced challenges with paper-heavy processes that risked errors and delays. Discover how digital solutions streamlined their operations and improved regulatory efficiency.
-
Reclaim Higher Quality Of Product With Efficient Filtration Strategies
Learn how the implementation of Pall’s Oenoflow™ HS lees filtration system has enabled the Barossa Valley winery to recover higher quality wine from lees more efficiently and economically.
-
How Community Oncologists View CAR T-Cell Therapy Possibilities And Challenges
Learn how a partner with innovative solutions aimed at overcoming the barriers that limit the real-world impact of CAR T-cell therapy can make these advanced therapies more accessible and affordable.
-
BioIVT Collaborates With IDBS To Deploy IDBS E-WorkBook And Reduce Study Cycle Times
Learn about a collaboration that has enabled BioIVT to enhance efficiency and responsiveness to its biopharmaceutical clients.
-
Impact Of Glycosylation On The Effector Functions Of Monoclonal Antibodies
In an example using rituximab and its biosimilars, explore the significance of minor differences of glycosylation in antibodies and its impact on their properties and functionality.
-
Geoinfo Services Designs A Low-Carbon Water System To Provide Clean, 24/7 Service To One Of India's Holiest Cities
In this case study, read about a network design that reduced energy use while improving health and quality of life for one of India's holiest cities.
-
Accelerating Approval Pathway For Phase III Ovarian Cancer Trial
A late-stage biotech developing a first-in-class therapy for a rare, chemo-resistant form of ovarian cancer sought help for accelerated FDA approval.
-
Laerdal Error-Proofs Medical Kit Assembly With AI-Powered Vision Verifications
Discover how Laerdal Medical implemented an automated kit assembly solution that enhances quality control and supports continuous improvement through real-time monitoring and visual documentation.
-
Revolutionizing European Football With UWB Micro-Location
See how UWB micro-location technology was utilized by European League Football to address pandemic-era challenges, but quickly transformed into a vital tool for player analytics and safety monitoring.
-
Partner Case Study: Accelerating Gene Editing Manufacturing
Beam Therapeutics partnered with ElevateBio to manufacture BEAM-101, a novel base editing therapy for sickle cell disease, advancing rapid, high-quality production towards clinical trials.
NEWS
-
NIH Funds Consortium To Accelerate Development Of New TB Treatments7/8/2024
A new consortium co-led by Weill Cornell Medicine, has been awarded a five-year, $31M grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases to accelerate the development of faster, more effective treatment regimens for tuberculosis (TB).
-
CARBOGEN AMCIS Shanghai Site Awarded Drug Manufacturing License From Chinese NMPA4/22/2025
CARBOGEN AMCIS, a Switzerland-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company is pleased to announce that its Shanghai facility has successfully obtained its first Drug Manufacturing License (DML) from China’s National Medical Products Administration (NMPA).
-
Decimal Point Analytics Launches DocuAgentIQ - Agentic AI Platform Transforming Document Workflows In SBA & CRE Lending8/23/2025
Decimal Point Analytics today announced DocuAgentIQ, a purpose-built Agentic AI platform that modernizes document-heavy work across SBA and CRE lending.
-
Evotec SE Announces First Projects For LAB eN2 Drug Discovery Accelerator With Novo Nordisk12/11/2024
Evotec SE announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture early research from academic institutions into novel therapeutics, has selected its first three projects to move forward in the program from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center.
-
New Device's Radio Waves Reveal Lead Contamination In Soil1/2/2025
Radio frequency (RF) signals are a cornerstone of modern technology, enabling wireless communication, data transfer and sensing applications across a wide range of fields and tasks.